Although CHIP may not ultimately be a suitable therapeutic approach for PD, it is still a valid approach for other protein-misfolding diseases such as Alzheimer's disease and Huntington's disease and was previously shown to degrade protein aggregates implicated in both diseases [12], [17], [18]. Here, STUB1 is linked to proteostasis deficiencies.